临床研发中的松弛素：过去、现在与未来
Serelaxin in clinical development: past, present and future.
作者信息
Unemori Elaine
机构信息
Oakland, CA, USA.
出版信息
Br J Pharmacol. 2017 May;174(10):921-932. doi: 10.1111/bph.13695. Epub 2017 Jan 29.
Abstract
UNLABELLED
The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long-term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure.
LINKED ARTICLES
This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
摘要
未标注
高纯度重组人松弛素（serelaxin）的可得性使得针对多种适应症开展了临床试验，并阐明了其在人体中的药理学特性。这些研究表明，serelaxin具有独特的血流动力学特性，这可能有助于在急性心力衰竭中实现器官保护和长期预后改善。临床观察结果支持将其考虑用于其他患者群体的治疗，包括慢性心力衰竭、冠状动脉疾病、门静脉高压症和急性肾衰竭患者。
相关文章
本文是关于松弛素家族肽及其受体认识的最新进展这一主题部分的一部分。要查看本部分的其他文章，请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc。
相似文献
1
Serelaxin in clinical development: past, present and future.
Br J Pharmacol. 2017 May;174(10):921-932. doi: 10.1111/bph.13695. Epub 2017 Jan 29.
2
The actions of relaxin on the human cardiovascular system.
Br J Pharmacol. 2017 May;174(10):933-949. doi: 10.1111/bph.13523. Epub 2016 Jul 11.
3
Serelaxin : a potential new drug for the treatment of acute heart failure.
Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28.
4
Recent progress in the understanding of relaxin family peptides and their receptors.
Br J Pharmacol. 2017 May;174(10):915-920. doi: 10.1111/bph.13778.
5
Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Cardiol Rev. 2016 Jul-Aug;24(4):194-204. doi: 10.1097/CRD.0000000000000089.
6
Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Cardiovasc Ther. 2017 Feb;35(1):55-63. doi: 10.1111/1755-5922.12231.
7
Serelaxin a novel treatment for acute heart failure.
Expert Rev Clin Pharmacol. 2015;8(5):549-57. doi: 10.1586/17512433.2015.1073587.
8
Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction.
Curr Protein Pept Sci. 2018;19(11):1079-1087. doi: 10.2174/1389203719666180709103020.
9
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):119-30. doi: 10.1093/ehjcvp/pvv046. Epub 2015 Nov 26.
10
Relaxin family peptides: structure-activity relationship studies.
Br J Pharmacol. 2017 May;174(10):950-961. doi: 10.1111/bph.13684. Epub 2017 Jan 19.
引用本文的文献
1
RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment.
Nat Commun. 2024 Aug 27;15(1):7263. doi: 10.1038/s41467-024-51571-8.
2
Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.
Sci Rep. 2022 Nov 28;12(1):20435. doi: 10.1038/s41598-022-24716-2.
3
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.
J Pers Med. 2022 Jun 21;12(7):1021. doi: 10.3390/jpm12071021.
4
Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.
Front Cardiovasc Med. 2021 Dec 14;8:760152. doi: 10.3389/fcvm.2021.760152. eCollection 2021.
5
Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes.
Nat Commun. 2021 Apr 9;12(1):2141. doi: 10.1038/s41467-021-22331-9.
6
Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity.
Basic Clin Androl. 2020 Mar 9;30:3. doi: 10.1186/s12610-020-0101-y. eCollection 2020.
7
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.
J Am Heart Assoc. 2019 Dec 17;8(24):e013465. doi: 10.1161/JAHA.119.013465. Epub 2019 Dec 10.
8
Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.
FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16.
9
Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis.
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12183-12192. doi: 10.1073/pnas.1900355116. Epub 2019 Jun 3.
10
Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.
Endocrine. 2018 Apr;60(1):103-111. doi: 10.1007/s12020-018-1534-3. Epub 2018 Feb 6.
本文引用的文献
1
Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
BMC Pregnancy Childbirth. 2016 Sep 5;16(1):260. doi: 10.1186/s12884-016-1046-1.
2
Cardiac Output and Renal Dysfunction: Definitely More Than Impaired Flow.
J Am Coll Cardiol. 2016 May 17;67(19):2209-2212. doi: 10.1016/j.jacc.2016.03.537.
3
Serelaxin: A Novel Therapeutic for Vascular Diseases.
Trends Pharmacol Sci. 2016 Jun;37(6):498-507. doi: 10.1016/j.tips.2016.04.001. Epub 2016 Apr 27.
4
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.
Br J Pharmacol. 2015 Dec;172(24):5744-869. doi: 10.1111/bph.13348.
5
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
6
Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
J Clin Pharmacol. 2016 Apr;56(4):474-83. doi: 10.1002/jcph.607. Epub 2015 Nov 4.
7
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.
J Hepatol. 2015 Apr;62(1 Suppl):S121-30. doi: 10.1016/j.jhep.2015.01.003.
8
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Circ J. 2015;79(6):1237-47. doi: 10.1253/circj.CJ-15-0227. Epub 2015 Apr 24.
9
Relaxin-2 does not ameliorate nephropathy in an experimental model of type-1 diabetes.
Kidney Blood Press Res. 2015;40(1):77-88. doi: 10.1159/000368484.
10
International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.
Pharmacol Rev. 2015;67(2):389-440. doi: 10.1124/pr.114.009472.
Zotero 插件